The biopharmaceutical industry is thriving, with breakthroughs in treating obesity, metabolic dysfunction-associated steatohepatitis (MASH), and retinal disease. While giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Merck & Co., Inc. (MRK) dominate the headlines, it's the clinical-stage biopharma companies trading under $20 that are more often associated with game-changing investment returns.
EyePoint Pharmaceuticals, Inc. (EYPT) and Altimmune, Inc. (ALT) are two small biotech stocks that Wall Street analysts expect to rally more than 200% within the next year. These types of early-stage, niche market players often carry high volatility and risk, but equally high potential. For investors ready to embrace the risk, these stocks might just be the ticket to substantial gains.
